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Abstract
Background: Although Chinese-origin Rhesus macaques (Ch RhMs) infected with simian immunodeficiency virus (SIV) have
been used for many years to evaluate the efficacy of AIDS vaccines and therapeutics, the bio-clinical variability of such a
nonhuman primate AIDS model was so far not established.
Methodology/Principal Findings: By randomizing 150 (78 male and 72 female) Ch RhMs with diverse MHC class I alleles
into 3 groups (50 animals per group) challenged with intrarectal (ir) SIVmac239, intravenous (iv) SIVmac239, or iv SIVmac251,
we evaluated variability in bio-clinical endpoints for 118 weeks. All SIV-challenged Ch RhMs became seropositive for SIV
during 1–2 weeks. Plasma viral load (VL) peaked at weeks 1–2 and then declined to set-point levels as from week 5. The set-
point VL was 30 fold higher in SIVmac239 (ir or iv)-infected than in SIVmac251 (iv)-infected animals. This difference in plasma
VL increased overtime (.100 fold as from week 68). The rates of progression to AIDS or death were more rapid in
SIVmac239 (ir or iv)-infected than in SIVmac251 (iv)-infected animals. No significant difference in bio-clinical endpoints was
observed in animals challenged with ir or iv SIVmac239. The variability (standard deviation) in peak/set-point VL was nearly
one-half lower in animals infected with SIVmac239 (ir or iv) than in those infected with SIVmac251 (iv), allowing that the
same treatment-related difference can be detected with one-half fewer animals using SIVmac239 than using SIVmac251.
Conclusion/Significance: These results provide solid estimates of variability in bio-clinical endpoints needed when
designing studies using the Ch RhM SIV model and contribute to the improving quality and standardization of preclinical
studies.
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Introduction
The nonhuman primate (NHP) models have been used for more
than two decades to evaluate HIV-1 vaccine candidates world-
wide. So far, no effective vaccine is available for preventing or
controlling HIV-1 infection. Due to the lack of clarity about what
host immune responses are required to prevent HIV-1/SIV
infection or to control viral replication/protect against disease
progression, the efficacy of prevention of viral infection or
protection of disease progression following experimental SIV
challenge of NHPs vaccinated with a prototype SIV vaccine is now
being reconsidered as the primary criterion to conclude go/no-go
decision prior to entry into phase I clinical trial [1,2]. Since the
HIV-1 does not replicate in most animal species hitherto tested,
including rodents and small non-human primates, SIV-HIV
chimera (SHIV) has been constructed by inserting partial genome
of HIV-1 into SIV and applied to infect rhesus monkeys as a
mimic animal model of HIV/AIDS ten years ago [3]. However,
the reliability of SHIV model has recently been doubted, since an
SIV version of the Merck Ad5 HIV-1 gag vaccine showed to be
effective in SHIV model [4] but proved to be ineffective for
protecting human from infection in the STEP clinical trials [5].
Interestingly, it has been shown after the human trials of the HIV-
1 vaccine that the SIV version of the Merck Ad5 HIV-1 gag
vaccine was also ineffective in reducing post-infection viral load of
vaccinated rhesus macaques after SIVmac239 challenge [6]. On
the other hand, some prototype SIV vaccines have been showed to
be only effective at reducing post-infection viral load in macaques
with a specific MHC class I allele, Mamu A*01 [7]. Furthermore,
certain MHC-1 alleles (such as Mamu A*01, Mamu B*08, and
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23177Mamu B*17) might be associated with an increased capacity to
control post-infection viral load in the absence of immunization
[8,9,10,11]. Therefore, the uses of appropriate SIV strains and
animals with diverse MCH-I alleles are critical for predicting the
outcome of a human clinical trial in cost-effective and resource-
efficient ways.
Up-to-date, SIV-infected rhesus macaques of Indian (In RhMs)
origin are among the most widely used NHP models for HIV/
AIDS. Although SIV-infected rhesus macaques of Chinese origin
(Ch RhMs) have also been used in the field for many years
[12,13,14,15], due to the relatively small size of animal numbers in
each individual study, it is very hard to define a standardized
model system with statistically meaningful parameters for the
evaluation or preclinical testing of candidate vaccines. In present
study, we undertook a prospective study to evaluate the virological,
immunological, and clinical evolutions of Ch Rh population
infected with SIVmac239 or SIVmac251 (the 2 frequently used
SIV strains) through different (intravenous versus intrarectal)
routes of viral challenge, aimed at developing a standardized
model system for any independent or coordinated NHN studies in
the field.
Results
MHC class I alleles in Ch RhMs
We started to genotype the MHC class I alleles using the SSP-
PCR assay in the PBMC samples taken from 150 Ch RhMs.
Twelve (A01, A02, A04, A11, A13, NA7, B01, B07, B12, B17,
NB2, and NB5) out of the 16 included RhM MHC-I alleles were
detected in Ch RhMs. The remaining 4 MHC-I alleles (A08, NA4,
B08, and NB4) were not detected in the 150 Ch RhMs. Of the 150
Ch RhM samples, 147 (98%) were found to have a single MHC-I
allele or multiple (2–5) shared Mamu-A and/or Mamu-B alleles
(Fig. 1a). Due to the complexity of Ch RhM MHC-I alleles, we
decided to distribute the animals to each group of the experiments
by randomization. The animals were then challenged with
intrarectal (ir) 10
5 TICD50 SIVmac239 (n=50) (Fig. 1b) or with
intravenous (iv) 200 TICD50 SIVmac239 (n=50) (Fig. 1c) or 200
TICD50 SIVmac251 (n=50) (Fig. 1d).
Antibody responses in SIV-infected Ch RhMs
As expected, all 150 Ch RhMs became seropositive for SIV 1–2
weeks after SIV challenges. The peak titers of plasma anti-SIV
Figure 1. Distribution of MHC class I alleles (including patterns of shared alleles) by the sequence-specific primers (SSP)-PCR assay
in the whole 150 Ch RhMs (A), 50 ir SIVmac239-infected Ch RhMs (B), 50 iv SIVmac239-infected Ch RhMs (C), or 50 iv SIVmac251-
infected Ch RhMs (D). Note that the 3 out of 150 (2%) samples were negative for the SSP-PCR assay.
doi:10.1371/journal.pone.0023177.g001
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IgA, and IgG respectively. No significant difference in plasma anti-
SIV antibody titers was observed between animals randomly
challenged with SIVmac239 (ir or iv) or SIVmac251 (iv) (P.0.1 by
Mann-Whitney) (Fig. 2a–c).
Disease progression in SIV-infected Ch RhMs
CD4
+ T-cell counts declined rapidly during the first 4 weeks
post-infection and decreased progressively thereafter in the 3
groups of animals (Fig. 3a). Kaplan-Meier analysis of the
probability of SIV-infected animals maintaining a CD4
+ T-cell
count over 350 cells/ml demonstrated that significant lower
probabilities to maintain a stable CD4
+ T-cell count were
observed in animals challenged with either intrarectal SIVmac239
(20%; T50: 52 weeks) (P,0.05) or intravenous SIV mac239 (8%;
T50: 68 weeks) (P,0.01) as compared to animals challenged with
intravenous SIVmac251 (48%; T50: 108 weeks) (Fig. 3b).
Kaplan-Meier survival analysis showed that animals challenged
with ir or iv SIVmac239 had lower survival rates (34% or 36% at
week 118) with a median survival time (T50) of 99 weeks for ir
SIVmac239 (95% confidence interval between 69 and 129) or 117
weeks for iv SIVmac239 (95% confidence interval between 101
and 134) as compared to those of animals challenged with
intravenous SIVmac251 (54% at week 118) with a T50 of .120
weeks (P,0.05) (Fig. 3c). Sixteen MHC-I B01-positive animals
infected with SIVmac239 were found to be associated with a
poorer survival (T50 of 54 weeks and 95% confidence interval
between 51 and 57) than those animals that were negative for
MHC-I B01 allele (T50 of 118 weeks and 95% confidence interval
between 92 and 144) (P,0.01) (Fig. 3d). A total of 88 animals (33,
32, and 23 for intrarectal SIVmac239, intravenous SIVmac239,
and intravenous SIV251 respectively) died from AIDS-defining
illness between 26 and 118 weeks post infection.
Plasma viral loads in SIV-infected Ch RhMs
The peaks of plasma viral loads (1–2 weeks) were similar
between these 3 groups of animals. The set-point viral loads were
around 30 fold lower in animals challenged with SIVmac239 (ir or
iv) as compared to those of animals challenged with SIVmac251
(iv) (P,0.01) and this difference increased to more than 100 fold as
from week 68 (P,0.01) (Fig. 4a). A more pronounced variation in
the set-point viral loads was observed in animals challenged with
intravenous SIVmac251 as compared to those of animals
challenged with intrarectal/intravenous SIVmac239 (P,0.01)
(Fig. 4b). Seventeen MHC-I B17-positive animals infected with
SIVmac239 were found to be associated with a lower set-point
viral load (nearly 10 fold) than those negative for MHC-I B17
allele (P,0.01) (Fig. 4c). We observed 4% and 6% of animals with
a persistent low viral load (,1000 copies/ml) in the intravenous
and intrarectal SIVmac239 challenge groups respectively, while
this figure was 28% in the intravenous SIVmac251 challenge
group.
Sample size estimations using SIV-infected Ch RhM
models
Having observed the distinct variations in the set-point viral
loads between animals challenged with SIVmac239 (ir or iv) or
SIVmac251 (iv), we performed statistical power calculation and
sample size estimation for Ch RhM AIDS model systems using the
peak viral load and the set-point viral load as endpoints. The peak
viral load was defined as the maximum viral load measured
between weeks 1–2 inclusive after SIV challenge for each animal
while the set-point viral load was defined as the average value for
an animal from weeks 5–10, as described previously [16]. To
estimate the variability for each of the 2 commonly used plasma
viral load measures, the overall standard deviation (SD) was
calculated for each of the 3 experimental groups. SD for peak viral
loads were similar for the 2 modes of SIVmac239 challenge (0.48
log10 SIV RNA copies/ml for ir and 0.50 log10 SIV RNA copies/
Figure 2. Humoral immune responses in Ch RhMs randomly
challenged with pathogenic SIVmac239 (ir or iv) or SIVmac251
(iv). (A) Anti-SIV IgM antibody titers (mean 6 SD) in plasma following
118 weeks post viral challenge. (B) Anti-SIV IgA antibody titers (mean 6
SD) in plasma following 118 weeks post viral challenge. (C) Anti-SIV IgG
antibody titers (mean 6 SD) in plasma following 118 weeks post viral
challenge.
doi:10.1371/journal.pone.0023177.g002
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copies/ml for ir and 0.79 log10 SIV RNA copies/ml for iv). In
contrast, SD for peak or set-point viral loads were substantially
higher in animals challenged with intravenous SIVmac251 (0.76
log10 SIV RNA copies/ml and 1.14 log10 SIV RNA copies/ml
respectively) as compared to SIVmac239 (ir or iv). These
variability estimates were then used to calculate the sample size
design using a commercial Power Analysis and Sample Size
software (PASS version 2008), assuming a two-group experiment
with groups of equal size and variability across groups. Due to a
lower variability, experiments using SIVmac239 (ir or iv) require
few animals than experiments using SIVmac251 to detect the
same difference. For example, 4/8 animals per group would be
required to detect a difference of 1.5 log10 SIV RNA copies/ml for
peak/set-point viral load between the two groups with 90% power
for either intrarectal or intravenous SIVmac239. Nearly twice as
many animals per group (7/14) would be required to detect the
same difference for peak/set-point viral loads using SIVmac251
(Table 1).
Discussion
Rhesus macaques of Indian and Chinese origin are commonly
used today in the animal models for studying a variety of human
diseases and vaccines. Ch RhMs differ from their Indian
counterparts in morphology and physiology [17,18], as well as in
their genetics [19,20,21,22]. Historically, In RhMs have been used
more frequently than Ch RhMs in research. However, there is a
trend of increasing use of Ch RhMs worldwide due to the long-
lasting embargo (since 70 s) on export of RhMs from India.
Previous SIV NHP studies have shown marked differences in
disease progression between Chinese- and Indian-origin macaques
[12,13,14,15]. In the present study (with a large number of
animals), we showed that randomized protocols for the use of Ch
RhM SIV model system could be standardized for testing AIDS
vaccines or therapeutics.
Although a previous study has reported no difference in survival
in In RhMs infected with either SIVmac239 or SIVmac251 [23],
we did observe that Ch RhMs infected with SIVmac239 by either
the intrarectal or intravenous route had higher viral loads than
SIVmac251 and progressed to AIDS more rapidly. This discrep-
ancy could results from the distinct MHC genes between In and Ch
RhMs [19,20,21,22]. In contrast to the molecularly cloned
SIVmac239 [24], the swarm (uncloned) SIVmac251 might raise a
more broad anti-viral immunity against the SIVmac251 quasispe-
cies in Ch RhMs to control viral load and to slow disease
progression. The fact that SIVmac239 (ir or iv)-infected Ch RhMs
had a higher and less variable set-point viral load and a more rapid
rate of progression to AIDS or death as compared to SIVmac251-
infected ChRhMs (Figs.3 and 4),implies a more advantage ofusing
SIVmac239-infected Ch RhM model in terms of shorter time for
achieving the clinical endpoints and smaller sample size require-
Figure 3. CD4+ T-cell counts and animal survivals in Ch RhMs randomly challenged with pathogenic SIVmac239 (ir or iv) or
SIVmac251 (iv). (A) Evolution of CD4
+ T-cell counts (mean 6 SD) following 118 weeks post viral challenge. (B) Kaplan-Meier plot of probability for
maintaining a stable CD4
+ T-cell count following 118 weeks post viral challenge. (C) Kaplan-Meier plot of survival probability of Ch RhMs following
118 weeks post viral challenge. (D) Survival curve of SIVmac239-infected Ch RhMs with or without MHC-I B01 allele.
doi:10.1371/journal.pone.0023177.g003
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SIVmac239-infected Ch RhM model system is also comparable
to the most frequently used SIVmac251-infected In RhMs in terms
of variability in the peak and set-point plasma viral loads
measurements [16]. The similar estimates of variability for peak
and set-point plasma viral loads as well as for clinical endpoints we
observed between intrarectal and intravenous SIVmac239 suggest
that SIV replicates in an overall similar lymphoid compartment
regardless the entry routes of infecting virus. Although it has been
suggested that humans infected withHIV-1 through different routes
of viral transmission (such as heterosexual or homosexual contact,
needle-sharing among injecting drug users, or blood transfusion)
might have different rates ofdisease progression [25,26], the reasons
for such differences have not-yet been clarified.
Figure 4. Plasma SIV RNA viral loads in Ch RhMs randomly challenged with pathogenic SIVmac239 (ir or iv) or SIVmac251 (iv). (A)
Evolution of plasma SIV RNA viral loads (geometric mean 6 SE) following 118 weeks post viral challenge. (B) Smoothed curve of the SIV RNA levels in
plasma of animals following 52 weeks post viral challenge with SIVmac239 (ir or iv) or SIVmac251 (iv). (C) Smoothed curve of the SIV RNA levels in
plasma of SIVmac239-infected Ch RhMs with or without MHC-I B17 allele.
doi:10.1371/journal.pone.0023177.g004
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elite controllers (EC: animals who had low viral loads for a time-
periodof.5 years)in nearly 1/3ofanimals[27], whileweobserved
only 4–6% of animals with a persistent low viral load (,1000
copies/ml) in the intravenous and intrarectal SIVmac239 challenge
groups. It is worth to note that the EC prevalencein HIV-1-infected
human population is ,0.5% [28]. Although the cause for such a
major discrepancy in the EC prevalence between the present study
and previous ones remains unknown, it might be however plausible
that such a discrepancy could result from distinct subspecies of Ch
RMs employed in different studies (a subspecies of Guangxi was
used in our study) since the complex subspecies of Ch RMs have
been indeed documented in China [29,30].
Rhesus macaque MHC-1 alleles Mamu A*01, Mamu B*08, and
Mamu B*17 have been suggested to be associated with an increased
capacity to control post-infection viral load in In RhMs
[8,9,10,11]. We observed that the MHC-1 Mamu B*08 allele was
absence in the 150 Ch RhMs and low frequencies of Ch RhMs
were positive for Mamu A*01 (3.3%) and Mamu B*17 (18%).
Indeed, the Mamu B*17 allele was found to be associated with a
significant lower set-point viral load in SIVmac239-infected Ch
RhMs as compared to those animals negative for Mamu B*17
(Fig. 4c), although no difference in survival was observed in
animals positive or negative for Mamu B*17 (data not shown). In
addition, we observed also that Mamu B*01 was associated with a
poorer survival (Fig. 3d), but no difference in viral load was
observed in SIVmac239-infected Ch RhMs positive or negative
for Mamu B*01 (data not shown). An early study has reported that
Mamu B*01 was associated with higher viral load in In RhMs
infected by SIVmac251 [31]. These discrepancies between viral
load and survival endpoints regarding to defined macaque MHC-1
alleles are most likely caused by a relatively low sensitivity of the
sequence-specific primers (SSP) PCR assays since one or two site-
mutation might switch off the outcome in a PCR-based assay.
Thus, further analysis by sequencing the full macaque MHC-1
genes should be required for establishing the potential link
between MHC-1 genotpyes/amino acid sequences and viro-
immunological makers in SIV-infected macaques. Nevertheless,
duo to the complexity of Ch RhM MHC-I molecules with multiple
shared alleles (Fig. 1), randomization of animals would be among
the most cost-effective and resource-efficient ways for evaluating
the efficacy of an experimental vaccine or drug in the animal
model system.
Given that large clinical trials aimed at inducing conventional
HIV-1-specific antibodies and/or CTL responses have failed to
show a significant clinical efficacy [6,32], it is now necessary to
search new alternative approaches for combating against AIDS
[33]. More recently, monoclonal antibodies directed against the
CD4-binding site of gp120 have been reported to be promising to
neutralize 90% of circulating HIV-1 isolates. However, whether
such broad neutralizing antibodies might be generated in vivo for
protecting people from either mucosal or systematic infection
should be further evaluated in the Ch or In RhM model system
before the start of a large human trial.
Materials and Methods
Animals
Colony-bred rhesus macaques (Macaca mulatta) of Chinese origin
(Ch RhM) (a subspecies of Guangxi) were housed at the non-
Table 1. Sample size requirements for each group with different powers and viral load (VL) measures.
Infecting virus Measures DD
a and power SD Sample size using estimated SD
SIVmac239-IV Peak VL
(1–2 weeks)
DD 1 1.25 1.5 1.75 2
80% 0.48 5 4 4 3 3
9 0 % 6 54 33
Set-point VL
(5–10 weeks)
DD 1 1.25 1.5 1.75 2
80% 0.85 13 9 7 5 5
90% 17 11 8 7 5
SIVmac239-IR Peak VL
(1–2 weeks)
DD 1 1.25 1.5 1.75 2
80% 0.50 6 4 4 3 3
9 0 % 7 54 43
Set-point VL
(5–10 weeks)
DD 1 1.25 1.5 1.75 2
80% 0.79 11 8 6 5 4
90% 15 10 7 6 5
SIVmac251-IV Peak VL
(1–2 weeks)
DD 1 1.25 1.5 1.75 2
80% 0.76 11 7 6 5 4
90% 14 9 7 6 5
Set-point VL
(5–10 weeks)
DD 1 1.25 1.5 1.75 2
80% 1.14 22 15 11 8 7
9 0 % 2 91 9 1 41 0 8
aMean detectable difference (DD) in log10 SIV RNA copies/ml between experimental and control groups.
doi:10.1371/journal.pone.0023177.t001
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Center (Guangdong, China) in accordance with the regulations
of the National Institutes of Health ‘Guide for the Care and Use of
Laboratory Animals’ and all details of animal welfare and steps
taken to ameliorate suffering were in accordance with the
recommendations of the Weatherall report, ‘‘The use of non-
human primates in research’’. Briefly, animals were housed in a
clean room (class D) with well-controlled temperature (20–25uC)
and humidity (30–70%). All parameters (temperature, humidity,
and pressure) were monitored in real time by a computer-based
continuous recording system. Each clean room had adequately
lighting and was equipped with 24 surrounding cages allowing the
animals have sight and sound of each other. The cage size was
1.2 m (length)61.2 m (wide)61.2 m (height) which had almost 2
fold more space than the minimum space recommended for a
group of nonhuman primate with a weight up to 10 kg by the
Institute for Laboratory Animal Research, National Research
Council of National Academy (USA) [34]. For the purpose of best
practice in environmental enrichment, each room was installed
with a loudspeaker providing 4 hours’ music per day (2 hours in
the morning and 2 hours in the afternoon) and each cage was
supplied with toys. Moreover, we implanted regular staff training
programs in order to ensure good standards of welfare. For
instance, improving the efficacy of anesthetic practices to prevent
animals from any unnecessary injury or training animals to present
a leg voluntarily for collecting a blood sample so as to avoid
anesthesia.
All animals were in good health, 3–6 years old, weighed 4–8 kg
and were seronegative for SIV, SRV, simian T cells lymphotropic
virus 1, hepatitis B virus, and Herpesvirus simiae (B virus). X ray
and skin test (PPD) were performed at entry for all animals to
exclude potential carriers of tuberculosis. This study was carried
out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National
Institute of Health. The protocol was approved by the Committee
on the Ethics of Animal Experiments of the Guangzhou University
of Chinese Medicine (Permit number: 15-0507). A total of 150 (78
males and 72 females) Ch RhMs were recruited for this
prospective study. To better control the bias, we assigned first
the 78 males and then the 72 females to 3 groups using the
computerized Random Number Generator Program (randnu-
m.exe) by adding the constraint of equal sample sizes after the
random numbers are distributed (i.e. 26 and 24 for males and
females respectively).
MHC class I typing
The rhesus macaque MHC class I alleles of 150 recruited Ch
RhMs were genotyped in peripheral blood monoculear cells
(PBMC) samples using sequence-specific primers (SSP) PCR assays
for representative Mamu-A and Mamu-B sequences as previously
described [8,10].
SIV challenges
SIVmac251 (3.2610
3 TCID50/ml) and SIVmac239 (5610
5
TCID50/ml) viruses (gifts of P.A. Marx in 1994) were propagated in
vitro using primary macaque PBMC and the first passages of the
original viral stocks were used for challenge. Briefly, PBMC were
isolated from whole blood of healthy Ch RhMs. After depleting
CD8 positive cells by MACS CD8 MicroBead (Miltenyi Biotec,
Auburn, CA) according to the manufacturer’s recommendations,
the cells were stimulated with 0.5 mg/mL staphylococcal Entero-
toxin B (SEB) (Sigma, St Louis, Missouri) for 3 days in RPMI 1640
containing 10% fetal bovine serum and 50 IU/mL rhIL-2. The
CD8-depleted/SEB-stimulated PBMC pooled from 20 Ch RhMs
were inoculated with SIVmac251 or SIVmac239 at 10
23 MOI for
2 hours, and were then cultured at a density of 10
6/mL in RPMI
1640 containing 10% fetal bovine serum and 50 IU/mL rhIL-2.
Half culture medium was replaced with the fresh culture medium
every other day, and cell-free supernatants between 6 and 20 days
post inoculation were collected. After the measurements of 50%
tissue-cell infectious doses (TCID50) titrated on CEM174 cells and
viral loads assayed by real-time PCR, the pooled supernatants
collected between 6 and 20 days were aliquoted and stored at
280uC until to use. The infectious doses of viral stocks used in this
study were 2610
5 TCID50/mL (2.3610
8 copies/mL) for SIV-
mac251 and 5610
5 TCID50/mL (3.4610
8 copies/mL) for
SIVmac239.
The animals (n=150) were randomly assigned into the 3
experimental groups: 1) challenged with intrarectal SIVmac239
(10
5 TICD50, n=50); 2) challenged with intravenous SIVmac239
(200 TICD50, n=50); and 3) challenged with intravenous
SIVmac251 (200 TICD50, n=50). Since SIVmac239 was cloned
from SIVmac251, we thought initially to compare the intravenous
versus intrarectal challenge of SIVmac239 for promoting the use
of molecularly cloned viral strain in order to reduce the bio-
variability in the NHP AIDS models. The intravenous uncloned
SIVmac251 challenge alone was included as a parallel control.
Before intrarectal inoculation, macaques were submitted to
40 hours of hydric diet (overnight plus whole day). Then, animals
were placed in a sternal position with the pelvis propped up at an
approximately 45u angle after being anesthetized (10 mg/kg of
body weight ketamine i.m. and 0.5 mg/kg xylazine i.m.). A
lubricated 2.5-mm-outer-diameter pediatric nasogastric-feeding
tube was inserted gently into the rectum of the animal
approximately 8 cm with caution so as to prevent mucosa trauma.
One ml of 1610
5 TCID50/mL virus was injected through the
catheter, followed by 2-ml air to push residual virus out without
viral dilution. The animal was kept tilted at a 45u angle and
remained immobile for at least 20 min after inoculation. For
intravenous challenge, 1 mL properly diluted virus were injected
into saphenous vein of anesthetized animals. The animals were
then followed up for 118 weeks thereafter. The dead animals were
diagnosed by autopsy as AIDS-defining illnesses (such as
opportunistic infections, lymphoma, meningitis or encephalitis).
Assay for antibodies
Anti-SIV IgG, IgM, and IgA antibodies in plasma were titrated
by an immunofluorescence antibody (IFA) assay [35], using FITC-
conjugated goal anti-macaque IgG (Sigma), IgM (ADI, San
Antonio, Texas), or IgA (ADI) antibodies. The sensitivity of IFA
assay was a titer of 8 for IgG and a titer of 4 for IgM and IgA.
Flow cytometry
Flow-cytometry analysis was carried out with FACScalibur (BD
Biosciences, San Jose, California) using fluorescence-labeled
monoclonal antibodies: CD3-PE-Cy7 (clone SP34-2), CD4-PE
(clone MT477), and CD8-PerCP (clone RPA-T8) (BD Bioscienc-
es).
Viral loads
Plasma SIV RNA was quantified by a quantitative RT-PCR
with primers (sense, 59-GAGGAAAAGAAATTT GGAGCAGA-
A-39; antisense, 59-GCTTGATGGTCTCCCACACAA-39) and
probe (59-FAM-AAAGTTGCACCCCCTATGACATTAATCA-
GATGTTA-TAMRA-39) using a 7500 Fast Real-Time PCR
System (Applied Biosystems, Foster City, California, USA). The
sensitivity of quantitative RT-PCR was 10 copies for the input SIV
Chinese-Origin Rhesus Macaque AIDS Model
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(100.000 g for 30 min).
Statistical analysis
The log-rank and Mann-Whitney tests were used for the
comparisons of impaired data between different groups of animals
and Kaplan-Meier survival analysis of animals with different viral
challenges was performed. A commercial Power Analysis and
Sample Size (PASS) software (version 2008) (National Computer
Systems & Services [NCSS], Kaysville, Utah) was used for
statistical power calculation and sample size estimation.
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